Navigation Links
Promising early evidence of the superior benefits of drug therapy for diabetic eye disease
Date:4/29/2008

April 29, 2008, New York, NY -- A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

These findings, representing the six-month end-point evaluation of the READ-2 clinical trial coordinated by The Johns Hopkins University, were presented Monday at the 2008 Annual Meeting of The Association for Research in Vision and Ophthalmology, in Fort Lauderdale, Florida.

According to Barbara Araneo, Ph.D., director of the complications program at JDRF, These are very encouraging results, showing that drugs we have been testing in human clinical trials can be effective in slowing or stopping the effects of eye disease brought on by diabetes.

The multi-center READ-2 Study (Ranibizumab for Edema of the mAcula in Diabetes), which began in December 2006, was designed to test the long-term safety and effectiveness of injections of the drug ranibizumab in patients with diabetic macular edema, a condition characterized by swelling of the central portion of the retina, or macula, at the back of the eye. In addition, the trial sought to determine the comparative efficacy of ranibizumab versus conventional treatment laser photocoagulation therapy or both together.

Macular edema, one of the most common causes of blindness, occurs when fluid and protein deposits collect on or under the macula, causing it to thicken and swell.

Participating in the clinical trial were 126 diabetic patients (average age 62) with documented Diabetic Macular Edema prior to enrollment; the majority had 20/80 vision in the eye that was treated. Patients were randomly assigned to receive one of three interventions: ranibizumab, laser photocoagulation, or a combination of the two treatments. At each visit over the course of the six-month treatment period, patients were evaluated for vision, retinal thickening, and general eye health. Although the study ended at six months, patients will be monitored for two years.

Patients treated with ranibizumab experienced significantly greater improvements in visual acuity, or clarity of vision, compared with patients receiving either of the other interventions. On average, the vision of ranibizumab-treated patients improved to 20/63 at month six, compared with essentially unchanged acuity scores of about 20/80 in both the laser and the combination treatment groups.

In addition, patients treated with ranibizumab had a 56 percent reduction in excess retinal thickness, whereas only an 11 percent reduction was seen in those receiving laser treatments.


'/>"/>

Contact: Leslie Schwartz
lschwartz@jdrf.org
212-479-7553
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related medicine news :

1. New Website Showcases 24 Promising Models That Are Transforming How Health Care Is Delivered
2. New HPV Vaccine Promising in Mice
3. Research promising for cystic fibrosis
4. Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets
5. Researchers Design Promising Cancer Drug
6. U-M researchers ID promising new cancer drug
7. UD researchers discover promising technique for repairing gene that causes spinal muscular atrophy
8. A promising new approach to cadmium induced hepatoxicity: Cytoprotective effect of midkine
9. Malaria Drug Promising Against Cancer
10. Results promising for computational quantum chemical methods for drug development
11. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Fla. (PRWEB) , ... February 20, 2017 , ... Johns ... research and education building. A topping out ceremony on Friday marked the halfway point ... building, set to open in Fall 2018, will serve as a center for innovation ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for ... Center in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017   Orion Health ... its Amadeus precision medicine platform to the ... currently manages over 110 million patient records globally. ... developing cloud-based, big data solutions built on modern, scalable ... Healthcare and Life Sciences. "The AWS Cloud gives healthcare ...
(Date:2/20/2017)... -- Research and Markets has announced the addition of ... Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic centers, ... their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised to ... This industry report analyzes the global markets for ...
(Date:2/20/2017)... 2017   Alberty   Drugs , ... has announced a significant shift in focus ... programs to servicing local Veteran Affairs Centers (VA) and ... an increased need to secure cost effective treatments for ... locally for their goods & services. "The ...
Breaking Medicine Technology: